--- Query Results --- | |||||||||||
Organization: | Alberta Precision Laboratories | ||||||||||
Message Alert: | PLEASE NOTE: This Test Directory is in an interim state and due to changes pertaining to the DynaLIFE transition, performing site for routing has not been updated. Please refer to Laboratory Information System for appropriate routing. | ||||||||||
Test Name/Synonym: | PML::RARA t(15;17) Translocation (Synonym: APL Transcript Analysis, t(15;17) PML::RARA, t(15;17) PML::RARA Quantitation) | ||||||||||
Clinical Indications: | Qualitative testing is performed for the investigation of acute leukemias. Quantitative testing is performed for treatment monitoring in acute leukemias. | ||||||||||
Test Includes: | Gene: PML::RARA | ||||||||||
Ordering Alert: | Physicians specifically requesting quantitative testing should defer to Molecular Pathology North Zone specimen and ordering requirements as quantitative testing is only performed at the University of Alberta site. | ||||||||||
Collection Alert: | In Calgary zone, test cannot be collected by Mobile Collection Service. All zones, unopened dedicated tubes are required for Molecular testing. | ||||||||||
LABID (Connect Care): | LAB4558 | ||||||||||
Specimen Type: | Bone marrow, Peripheral blood | ||||||||||
Specimen Source: | Indicate a specimen source. | ||||||||||
Primary Container: | See Specimen Collection Requirements | ||||||||||
Minimum Collection Volume: | See Specimen Collection Requirements | ||||||||||
Specimen Collection Requirements: |
| ||||||||||
Test Resources: | Submit request using the applicable requisition or Connect Care online order entry:
Please ensure all required information, including patient's clinical history/indication, is provided on the requisition. | ||||||||||
Stability and Storage: | Refrigerated until ready for transport. | ||||||||||
Processing: |
| ||||||||||
Transportation: |
| ||||||||||
Method and Interpretation of Results: | Molecular Pathology North Qualitative test method: Real-time PCR RNA extraction was performed on the QIAsymphony. cDNA synthesis and amplification of t(15;17) gene transcripts was performed in two steps by RT qPCR with ABL1 as the reference gene. Fluorescence detection was by the QuantStudio real time PCR platform (Life Technologies). Appropriate positive and negative controls were used. The limit of detection (LOD) of this assay is a 5.0 log reduction from the mean of pooled positive diagnostic samples. Quantitative test method: Real-time PCR RNA extraction was performed on the QIAsymphony. cDNA synthesis and quantitation of t(15;17) gene transcripts was performed in two steps by RT-qPCR with ABL1 as the reference gene. Fluorescence detection was by the QuantStudio real time PCR platform (Life Technologies). Appropriate positive and negative controls were used. The results are expressed as percentage residual disease and a calculated log reduction (LR). The residual disease is the percentage of NCN of the monitor sample to the NCN of the initial diagnostic sample. The LR is the log reduction in the normalized copy number (NCN) of PML/RARA transcript from the initial diagnostic sample. The NCN is the ratio of PML/RARA transcripts to ABL1 transcripts. The limit of detection (LOD) of this assay is a 5.0-log reduction from the mean of pooled positive diagnostic samples, which corresponds to 0.001% residual disease. | ||||||||||
Routine Turn Around Time: |
| ||||||||||
Testing Schedule: |
| ||||||||||
Testing Area: | Molecular Pathology | ||||||||||
Performing Site: | University of Alberta Hospital | ||||||||||
Additional Test Information: | PAXgene® collection tubes are available upon request. Submit an order as per online Client Order Form Submission process. Details in following document: RR01-005 Ordering Supplies from Reagent Room | ||||||||||
Contact Comments: |
| ||||||||||
Last Updated On: | Friday, December 13, 2024 | ||||||||||
Date of Last Review: | Oct 21 2024 12:00AM | ||||||||||
Registered Trademark Comments: | PAXgene® is a trademark of PreAnalytiX GmbH. |